Data in Brief

Microarray-based analysis of plasma cirDNA epigenetic modification profiling in xenografted mice exposed to intermittent hypoxia

Rene Cortese, Isaac Almendros 1, Yang Wang, David Gozal *

Section of Pediatric Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, The University of Chicago, Chicago, IL, United States

A B S T R A C T

Intermittent hypoxia (IH) during sleep is one of the major abnormalities occurring in patients suffering from obstructive sleep apnea (OSA), a highly prevalent disorder affecting 6–15% of the general population, particularly among obese people. IH has been proposed as a major determinant of oncogenetically-related processes such as tumor growth, invasion and metastasis. During the growth and expansion of tumors, fragmented DNA is released into the bloodstream and enters the circulation. Circulating tumor DNA (cirDNA) conserves the genetic and epigenetic profiles from the tumor of origin and can be isolated from the plasma fraction. Here we report a microarray-based epigenetic profiling of cirDNA isolated from blood samples of mice engrafted with TC1 epithelial lung cancer cells and controls, which were exposed to IH during sleep (XenoIH group, n = 3) or control conditions, (i.e., room air (RA); XenoRA group, n = 3) conditions. To prepare the targets for microarray hybridization, we applied a previously developed method that enriches the modified fraction of the cirDNA without amplification of genomic DNA. Regions of differential cirDNA modification between the two groups were identified by hybridizing the enriched fractions for each sample to Affymetrix GeneChip Human Promoter Arrays 1.0R. Microarray raw and processed data were deposited in NCBI’s Gene Expression Omnibus (GEO) database (accession number: GSE61070).

© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Direct link to deposited data

http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61070.

2. Experimental design, materials and methods

2.1. Experimental design

Fig. 1 provides a schematic representation of the design for the full study, as previously reported [2]. Mice injected with tumor TC1 cells and control mice were exposed to intermittent hypoxia (IH) during sleep, or room air (RA) conditions (see below for details). Large scale DNA methylation profiles of circulating DNA were produced in plasma cirDNA samples from xenografted mice exposed to IH (XenoIH group, n = 3) or to RA (XenoRA group, n = 3) conditions using a method that enriches the modified fraction of the cirDNA without amplification of genomic DNA [1] (Fig. 2). Regions of differential cirDNA modification between the XenoIH and XenoRA group were identified by hybridizing the enriched fractions for each sample to Affymetrix GeneChip Human Promoter Array 1.0R.

http://dx.doi.org/10.1016/j.gdata.2015.05.004
2213-5960/© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2.2. Materials and methods

2.2.1. Animals, hypoxic exposures, and epithelial lung tumor model

C57BL/6J male mice (7-week old) were acquired from Jackson Laboratories (Bar Harbor, ME). Mice were pre-exposed during 2 weeks to either RA or IH during the daylight phase corresponding to the preferred sleep period, and were then injected with $1 \times 10^5$ TC1 murine lung tumor cells in the left flank. The protocol for IH exposure was previously described by our group and consisted of alternating cycles of 90 s (6% fraction of inspired oxygen (FiO2) followed by 21% FiO2) for 12 h/day (7 AM to 7 PM). With this paradigm, the oxyhemoglobin saturation at the end of the hypoxic period reaches to 65%–72% mimicking that experienced by moderate to severe OSA patients. For the rest of the day (7 PM to 7 AM) the mice were in normoxic conditions (21% FiO2). Gas mixture was electronically controlled by an internal analyzer which can receive in real-time the O2 values inside of the chamber and can automatically modify by a computerized system of solenoid valves the gas mixture to follow the programmed gas profile. After 4 weeks from tumor injection, mice were sacrificed and tumors excised and weighed.

All experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of Chicago.

2.2.2. Plasma cirDNA and genomic DNA isolation

Blood samples were collected after being sacrificed and immediately processed. The plasma fraction was separated by centrifugation and
cirDNA was isolated using the QIAamp Nucleic Acid isolation kit (Qiagen, Valencia, CA) according to the manufacturer’s instruction.

2.2.3. cirDNA modification profiling

Large-scale cirDNA epigenetic modification profiles were assessed according to previously described methods [1]. Briefly, universal DNA adaptors were ligated to the ends of cirDNA fragments, followed by digestion with DNA modification-sensitive enzymes and amplification by adaptor-mediated PCR (Fig. 2).

2.2.4. Microarray hybridization and processing

The enriched differentially cirDNA modified fraction was fragmented, biotin-labeled, and hybridized on Affymetrix GeneChip Mouse Promoter Array 1.0R (Affymetrix, Santa Clara, CA) and scanned, according to the manufacturer’s protocol. The array consisted of over 4.6 million probes tiled to interrogate over 28,000 mouse promoter regions. Promoter regions were selected from annotated genes in public databases (33,559 Ensembl genes (version 30.33f), 18,167 RefSeq mRNAs (NCBI GenBank) and 27,707 complete-CDS mRNAs (NCBI GenBank)). Probes were 25-mer long, leaving 10-mer separation between adjacent probes, providing a 35 base pair resolution. Each promoter region was cover by a 10 kb segment.

2.2.5. Microarray data analysis

Microarray raw and processed data were deposited in NCBI’s Gene Expression Omnibus (GEO) database (accession number: GSE61070). Raw files (.cel) were produced using GCOS 1.3 software (Affymetrix).

Data quality control. Data quality control was performed using the STARR package [5] in the R statistical environment (version 3.0.2) [6]. Probe annotation was provided by the manufacturer (Mm_PromPR_v02-1_NCBilv36.bmap file; Affymetrix). The absence of hybridization artifacts was verified by building pseudoimage plots for each array. Paired scatter plots were produced to determine the signal distribution correlation between each array (Fig. 3). Signal distributions before and after normalization were assessed by density plots, as well as the correction of bias due to GC-content differences (Supplementary Fig. S2 in [2]). Microarray signals in each microarray were loess-normalized and M–A plots produced to detect technical variation that may mask true biological differences [7] (Fig. 4). No outliers were detected and all arrays were included in the assessment of differential cirDNA modification.

Assessment of differential cirDNA modification. Data were analyzed using the Partek Genomic Suite Software (PGS) (St. Louis, MO). Signals were adjusted according to the probe sequence and background corrected using the Robust Microarray method (RMA) [8]. One-way ANOVA was used to detect probes showing differential cirDNA modification between the groups. The significance level was set at \( p < 0.05 \) and fold changes higher than 2. Model-based analysis of tiling-arrays (MAT) [9] was used to identify regions of differential cirDNA modification by combining adjacent probes showing significant differences between the groups. A sliding window of 500 bp was set, according to the average size of the fragments produced in the amplicon preparation step [1].

Fig. 3. Signal intensity correlation among arrays before normalization. Paired scatter plots of signal intensity for each array in the set. Signal intensity values (before normalization) for each array are plotted in the X- and Y axes, respectively. Red line depicts the correlation trend lines. Correlation coefficient for each pair is indicated.
Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

This work was supported in part by the Herbert T. Abelson Chair in Pediatrics.

References

[1] R. Cortese, A. Kwan, E. Lalonde, O. Bryzgunova, A. Bondar, Y. Wu, J. Gordevicius, M. Park, G. Oh, Z. Kaminsky, J. Tverkuviene, A. Laurinavicius, F. Jankevicius, D.H. Sendorek, S. Haider, S.C. Wang, S. Jarmalaite, P. Laktionov, P.C. Boutros, A. Petronis, Epigenetic markers of prostate cancer in plasma circulating DNA. Hum. Mol. Genet. 21 (16) (2012) 3619–3631, http://dx.doi.org/10.1093/hmg/dds192 PubMed PMID: 22619380.

[2] R. Cortese, I. Almendros, Y. Wang, D. Gozal, Tumor circulating DNA profiling in xenografted mice exposed to intermittent hypoxia. Oncotarget 6 (1) (2015) 556–569 PubMed PMID: 25415227; PMCID: 4381615.

[3] I. Almendros, Y. Wang, L. Becker, F.E. Lennon, J. Zheng, B.R. Coats, K.S. Schoenfelt, A. Carreras, F. Hakim, S.X. Zhang, R. Farre, D. Gozal, Intermittent hypoxia-induced changes in tumor-associated macrophages and tumor malignancy in a mouse model of sleep apnea. Am. J. Respir. Crit. Care Med. 189 (5) (2014) 593–601, http://dx.doi.org/10.1164/rccm.201310-1830OC PubMed PMID: 24471484; PMCID: 3977114.

[4] A. Carreras, F. Kayali, J. Zhang, C. Hirotsu, Y. Wang, D. Gozal, Metabolic effects of intermittent hypoxia in mice: steady versus high-frequency applied hypoxia daily during the rest period. Am. J. Physiol. Regul. Integr. Comp. Physiol. 303 (7) (2012) R700-9, http://dx.doi.org/10.1152/ajpregu.00258.2012 PubMed PMID: 22895743; PMCID: 3469669.

[5] B. Zacher, P. Torkler, A. Tresch, Analysis of Affymetrix ChIP-chip data using starr and R/Bioconductor. Cold Spring Harbor Protocols (5) (2011) pdb top110. PubMed PMID: 21536772.

[6] R.C. Team, R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2014.

[7] J.D. Storey, R. Tibshirani, Statistical Methods for Identifying Differentially Expressed Genes in DNA Microarrays. 2003. 149–157.

[8] R.A. Irizarry, B. Hobbs, F. Collin, Y.D. Beazer-Barclay, K.J. Antonellis, U. Scherf, T.P. Speed, Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Bioinformatics 4 (2) (2003) 249–264, http://dx.doi.org/10.1093/biostatistics/kxg033 PubMed PMID: 12925520.

[9] W.E. Johnson, W. Li, C.A. Meyer, R. Gottardo, J.S. Carroll, M. Brown, X.S. Liu, Model-based analysis of tiling-arrays for ChIP-chip. Proc. Natl. Acad. Sci. U. S. A. 103 (33) (2006) 12457–12462, http://dx.doi.org/10.1073/pnas.0601180103 PubMed PMID: 16895995; PMCID: PMC1567901.